RU2015124805A - Оптимизированные с помощью вычислительных средств антигены с широким спектром реактивности для вируса гриппа h1n1 - Google Patents
Оптимизированные с помощью вычислительных средств антигены с широким спектром реактивности для вируса гриппа h1n1 Download PDFInfo
- Publication number
- RU2015124805A RU2015124805A RU2015124805A RU2015124805A RU2015124805A RU 2015124805 A RU2015124805 A RU 2015124805A RU 2015124805 A RU2015124805 A RU 2015124805A RU 2015124805 A RU2015124805 A RU 2015124805A RU 2015124805 A RU2015124805 A RU 2015124805A
- Authority
- RU
- Russia
- Prior art keywords
- seq
- influenza virus
- residues
- polypeptide
- vlp
- Prior art date
Links
- 206010069767 H1N1 influenza Diseases 0.000 title 1
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 230000009257 reactivity Effects 0.000 title 1
- 201000010740 swine influenza Diseases 0.000 title 1
- 241000712461 unidentified influenza virus Species 0.000 claims 39
- 101710154606 Hemagglutinin Proteins 0.000 claims 33
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims 33
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims 33
- 101710176177 Protein A56 Proteins 0.000 claims 33
- 229920001184 polypeptide Polymers 0.000 claims 30
- 108090000765 processed proteins & peptides Proteins 0.000 claims 30
- 102000004196 processed proteins & peptides Human genes 0.000 claims 30
- 239000000185 hemagglutinin Substances 0.000 claims 24
- 238000000034 method Methods 0.000 claims 24
- 125000003275 alpha amino acid group Chemical group 0.000 claims 16
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 11
- 108020001507 fusion proteins Proteins 0.000 claims 10
- 102000037865 fusion proteins Human genes 0.000 claims 10
- 206010022000 influenza Diseases 0.000 claims 10
- 108020004707 nucleic acids Proteins 0.000 claims 10
- 102000039446 nucleic acids Human genes 0.000 claims 10
- 150000007523 nucleic acids Chemical class 0.000 claims 10
- 102000005348 Neuraminidase Human genes 0.000 claims 8
- 108010006232 Neuraminidase Proteins 0.000 claims 8
- 239000003937 drug carrier Substances 0.000 claims 8
- 239000002245 particle Substances 0.000 claims 8
- 238000006467 substitution reaction Methods 0.000 claims 7
- 239000002671 adjuvant Substances 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 230000028993 immune response Effects 0.000 claims 4
- 230000003053 immunization Effects 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 108020004705 Codon Proteins 0.000 claims 2
- 108060003393 Granulin Proteins 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 238000005457 optimization Methods 0.000 claims 2
- 108700010900 influenza virus proteins Proteins 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261730186P | 2012-11-27 | 2012-11-27 | |
| US61/730,186 | 2012-11-27 | ||
| PCT/US2013/072279 WO2014085616A1 (en) | 2012-11-27 | 2013-11-27 | Computationally optimized broadly reactive antigens for h1n1 influenza |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015124805A true RU2015124805A (ru) | 2017-01-13 |
Family
ID=50773495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015124805A RU2015124805A (ru) | 2012-11-27 | 2013-11-27 | Оптимизированные с помощью вычислительных средств антигены с широким спектром реактивности для вируса гриппа h1n1 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US9309290B2 (enExample) |
| EP (1) | EP2925773B1 (enExample) |
| JP (2) | JP2016505538A (enExample) |
| KR (1) | KR20150089005A (enExample) |
| CN (1) | CN104797594A (enExample) |
| AU (2) | AU2013352179B2 (enExample) |
| CA (1) | CA2891682A1 (enExample) |
| HK (1) | HK1212708A1 (enExample) |
| IN (1) | IN2015DN03070A (enExample) |
| MX (1) | MX2015005056A (enExample) |
| RU (1) | RU2015124805A (enExample) |
| SG (1) | SG11201503989PA (enExample) |
| WO (1) | WO2014085616A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2616545B1 (en) * | 2010-09-14 | 2018-08-29 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Computationally optimized broadly reactive antigens for influenza |
| JP6113155B2 (ja) * | 2011-06-20 | 2017-04-12 | ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 計算で最適化した広い反応性を示すｈ１ｎ１インフルエンザの抗原 |
| RU2639551C2 (ru) | 2012-03-30 | 2017-12-21 | Юниверсити Оф Питтсбург - Оф Зе Коммонвэлс Систем Оф Хайе Эдьюкейшн | Оптимизированные с помощью вычислительных средств антигены с широким спектром реактивности для вирусов гриппа h5n1 и h1n1 |
| JP6764408B2 (ja) * | 2014-12-19 | 2020-09-30 | オレゴン ヘルス アンド サイエンス ユニバーシティー | Ｈ１ｎ１インフルエンザに対するコンピュータ最適化広反応性抗原の相乗的併用投与 |
| AU2016274770B2 (en) * | 2015-06-09 | 2020-11-12 | Sanofi Pasteur, Inc. | Methods of optimizing nucleotide sequences encoding engineered influenza proteins |
| US11116832B2 (en) | 2016-06-03 | 2021-09-14 | Sanofi Pasteur Inc. | Modification of engineered influenza hemagglutinin polypeptides |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001268662A1 (en) | 2000-06-23 | 2002-01-08 | Wyeth Holdings Corporation | Assembly of wild-type and chimeric influenza virus-like particles (VLPs) |
| US20050181459A1 (en) | 2002-06-11 | 2005-08-18 | Matthew Baker | Method for mapping and eliminating T cell epitopes |
| US8592197B2 (en) | 2003-07-11 | 2013-11-26 | Novavax, Inc. | Functional influenza virus-like particles (VLPs) |
| CA2598884A1 (en) | 2005-02-24 | 2006-10-05 | University Of Massachusetts | Influenza nucleic acids, polypeptides, and uses thereof |
| MX2008000890A (es) | 2005-07-19 | 2008-03-18 | Dow Global Technologies Inc | Vacunas de influenza (flu) recombinantes. |
| EP1969510A2 (en) | 2005-12-19 | 2008-09-17 | Novartis Vaccines and Diagnostics S.r.l. | Methods of clustering gene and protein sequences |
| US20080045472A1 (en) | 2006-03-31 | 2008-02-21 | Council Of Scientific And Industrial Research Bharat Biotech | Targets for human micro rnas in avian influenza virus (h5n1) genome |
| WO2008028946A2 (en) | 2006-09-07 | 2008-03-13 | Crucell Holland B.V. | Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof |
| EP2185195A2 (en) | 2007-08-16 | 2010-05-19 | Tripep Ab | Immunogen platform |
| EP2217064A4 (en) * | 2007-11-12 | 2012-10-03 | Univ Pennsylvania | NEW VACCINES FOR FIGHT AGAINST SEVERAL SUBTYPES OF INFLUENZA VIRUSES |
| EA034733B1 (ru) * | 2008-01-21 | 2020-03-13 | Медикаго Инк. | Нуклеиновая кислота для увеличенной экспрессии гемагглютинина вируса гриппа в растении и ее применение |
| US7981428B2 (en) | 2008-01-23 | 2011-07-19 | Academia Sinica | Flu vaccines and methods of use thereof |
| WO2010036970A2 (en) | 2008-09-25 | 2010-04-01 | Fraunhofer Usa, Inc. | Influenza vaccines, antigens, compositions, and methods |
| US20110177122A1 (en) | 2008-09-26 | 2011-07-21 | The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services | Dna prime/activated vaccine boost immunization to influenza virus |
| US8871220B2 (en) | 2009-04-03 | 2014-10-28 | Merial Limited | Newcastle disease virus vectored avian vaccines |
| EP2445928B1 (en) * | 2009-06-24 | 2018-03-28 | Medicago Inc. | Chimeric influenza virus-like particles comprising hemagglutinin |
| US8298820B2 (en) | 2010-01-26 | 2012-10-30 | The Trustees Of The University Of Pennsylvania | Influenza nucleic acid molecules and vaccines made therefrom |
| US20110184160A1 (en) * | 2010-01-26 | 2011-07-28 | Weiner David B | Nucleic acid molecule encoding consensus influenza a hemagglutinin h1 |
| CN102373184A (zh) * | 2010-08-09 | 2012-03-14 | 中山大学 | 禽流感和传染性支气管炎混合病毒样颗粒、制备方法和应用 |
| EP2616545B1 (en) * | 2010-09-14 | 2018-08-29 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Computationally optimized broadly reactive antigens for influenza |
| JP6113155B2 (ja) * | 2011-06-20 | 2017-04-12 | ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 計算で最適化した広い反応性を示すｈ１ｎ１インフルエンザの抗原 |
| RU2018113521A (ru) | 2012-02-07 | 2019-03-04 | Юниверсити Оф Питтсбург - Оф Зе Коммонвэлс Систем Оф Хайе Эдьюкейшн | Рекомбинантный полипептид гемагглютинин (ha) вируса гриппа для вызова иммунного ответа в отношении вирусов гриппа h2n2 или b |
| CA2863949C (en) | 2012-02-13 | 2021-06-29 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Computationally optimized broadly reactive antigens for human and avian h5n1 influenza |
| RU2639551C2 (ru) * | 2012-03-30 | 2017-12-21 | Юниверсити Оф Питтсбург - Оф Зе Коммонвэлс Систем Оф Хайе Эдьюкейшн | Оптимизированные с помощью вычислительных средств антигены с широким спектром реактивности для вирусов гриппа h5n1 и h1n1 |
-
2013
- 2013-11-27 US US14/092,371 patent/US9309290B2/en active Active
- 2013-11-27 CA CA2891682A patent/CA2891682A1/en not_active Abandoned
- 2013-11-27 RU RU2015124805A patent/RU2015124805A/ru not_active Application Discontinuation
- 2013-11-27 IN IN3070DEN2015 patent/IN2015DN03070A/en unknown
- 2013-11-27 AU AU2013352179A patent/AU2013352179B2/en not_active Ceased
- 2013-11-27 CN CN201380060899.XA patent/CN104797594A/zh active Pending
- 2013-11-27 MX MX2015005056A patent/MX2015005056A/es unknown
- 2013-11-27 SG SG11201503989PA patent/SG11201503989PA/en unknown
- 2013-11-27 JP JP2015544208A patent/JP2016505538A/ja active Pending
- 2013-11-27 HK HK16100529.2A patent/HK1212708A1/zh unknown
- 2013-11-27 KR KR1020157012693A patent/KR20150089005A/ko not_active Withdrawn
- 2013-11-27 EP EP13859229.0A patent/EP2925773B1/en not_active Not-in-force
- 2013-11-27 WO PCT/US2013/072279 patent/WO2014085616A1/en not_active Ceased
-
2016
- 2016-02-24 US US15/051,991 patent/US9566328B2/en active Active
- 2016-12-28 US US15/392,710 patent/US10017544B2/en active Active
-
2018
- 2018-03-15 AU AU2018201876A patent/AU2018201876A1/en not_active Abandoned
- 2018-06-29 JP JP2018124432A patent/JP2018183149A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201503989PA (en) | 2015-06-29 |
| HK1212708A1 (zh) | 2016-06-17 |
| EP2925773A4 (en) | 2016-06-08 |
| US9566328B2 (en) | 2017-02-14 |
| US20140147459A1 (en) | 2014-05-29 |
| JP2018183149A (ja) | 2018-11-22 |
| US10017544B2 (en) | 2018-07-10 |
| MX2015005056A (es) | 2015-07-23 |
| AU2013352179A1 (en) | 2015-05-14 |
| CA2891682A1 (en) | 2014-06-05 |
| IN2015DN03070A (enExample) | 2015-10-02 |
| KR20150089005A (ko) | 2015-08-04 |
| JP2016505538A (ja) | 2016-02-25 |
| EP2925773A1 (en) | 2015-10-07 |
| US9309290B2 (en) | 2016-04-12 |
| WO2014085616A1 (en) | 2014-06-05 |
| AU2013352179A8 (en) | 2015-05-28 |
| US20160166677A1 (en) | 2016-06-16 |
| AU2018201876A1 (en) | 2018-04-12 |
| US20170114102A1 (en) | 2017-04-27 |
| EP2925773B1 (en) | 2018-12-26 |
| AU2013352179B2 (en) | 2017-12-21 |
| CN104797594A (zh) | 2015-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014101401A (ru) | Антигены вируса гриппа h1n1 с широким спектром активности, оптимизированные с применением вычислительных средств | |
| RU2014142785A (ru) | Оптимизированные с помощью вычислительных средств антигены с широким спектром реактивности для вирусов гриппа h5n1 и h1n1 | |
| RU2018113521A (ru) | Рекомбинантный полипептид гемагглютинин (ha) вируса гриппа для вызова иммунного ответа в отношении вирусов гриппа h2n2 или b | |
| JP6957580B2 (ja) | 新規多価ナノ粒子に基づくワクチン | |
| JP2015506705A5 (enExample) | ||
| Li et al. | SARS-CoV-2 spike produced in insect cells elicits high neutralization titres in non-human primates | |
| RU2015124805A (ru) | Оптимизированные с помощью вычислительных средств антигены с широким спектром реактивности для вируса гриппа h1n1 | |
| RU2019139064A (ru) | Композиции и способы для лечения цитомегаловируса | |
| EP3464331B1 (en) | Stabilized pre-fusion rsv f proteins | |
| RU2011128371A (ru) | Модифицированные f протеины sv и способы их применения | |
| RS61456B1 (sr) | Stabilizovani rastvorljivi pre-fuzioni rsv f protein za primenu u profilaksi rsv infekcije | |
| JP2015119730A5 (enExample) | ||
| CN103547676A (zh) | 颗粒形式的免疫原性组合物和用于产生其的方法 | |
| JP2016505538A5 (enExample) | ||
| WO2023110618A1 (en) | Stabilized pre-fusion hmpv fusion proteins | |
| JP2014519817A5 (enExample) | ||
| WO2017207477A1 (en) | Stabilized pre-fusion rsv f proteins | |
| Li et al. | A self-assembled nanoparticle vaccine elicits effective neutralizing antibody response against EBV infection | |
| EP2773674A1 (en) | Immunologic constructs and methods | |
| US9163068B2 (en) | Influenza virus recombinant proteins | |
| Krammer et al. | Influenza virus-like particles as an antigen-carrier platform for the ESAT-6 epitope of Mycobacterium tuberculosis | |
| CN115850395A (zh) | 一种流感病毒通用型纳米颗粒疫苗及其制备方法 | |
| JP2011088864A (ja) | インフルエンザウイルスに対するベクターワクチン | |
| CN109821014B (zh) | 一种多抗原仿生流感疫苗及其制备方法和应用 | |
| CA3213403A1 (en) | Modified chimeric coronavirus spike protein for enhancement of viral titers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20190523 |